Poseida Therapeutics (NASDAQ:PSTX) Hits New 12-Month High at $7.44

Poseida Therapeutics, Inc. (NASDAQ:PSTXGet Rating)’s stock price reached a new 52-week high during trading on Friday . The company traded as high as $7.44 and last traded at $7.44, with a volume of 9438 shares trading hands. The stock had previously closed at $7.11.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on PSTX shares. BTIG Research reduced their target price on Poseida Therapeutics from $20.00 to $14.00 in a research report on Friday, November 11th. HC Wainwright assumed coverage on Poseida Therapeutics in a report on Wednesday, January 4th. They issued a “buy” rating and a $15.00 price objective on the stock.

Poseida Therapeutics Price Performance

The stock has a market capitalization of $642.90 million, a price-to-earnings ratio of -11.00 and a beta of 0.12. The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.64 and a current ratio of 6.64. The company has a 50 day moving average of $5.50 and a 200 day moving average of $4.24.

Poseida Therapeutics (NASDAQ:PSTXGet Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $1.60. The business had revenue of $116.31 million during the quarter, compared to analysts’ expectations of $2.00 million. Poseida Therapeutics had a negative return on equity of 21.56% and a negative net margin of 19.26%. As a group, equities research analysts anticipate that Poseida Therapeutics, Inc. will post -0.4 EPS for the current year.

Institutional Trading of Poseida Therapeutics

A number of large investors have recently made changes to their positions in PSTX. EcoR1 Capital LLC purchased a new stake in Poseida Therapeutics during the 3rd quarter valued at approximately $9,355,000. Silverarc Capital Management LLC raised its stake in Poseida Therapeutics by 571.1% during the 3rd quarter. Silverarc Capital Management LLC now owns 2,554,277 shares of the company’s stock valued at $9,017,000 after acquiring an additional 2,173,671 shares during the last quarter. Cormorant Asset Management LP purchased a new stake in Poseida Therapeutics during the 3rd quarter valued at approximately $6,531,000. Vanguard Group Inc. raised its stake in Poseida Therapeutics by 79.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,384,866 shares of the company’s stock valued at $8,419,000 after acquiring an additional 1,059,216 shares during the last quarter. Finally, Pentwater Capital Management LP raised its stake in Poseida Therapeutics by 20.3% during the 3rd quarter. Pentwater Capital Management LP now owns 5,975,000 shares of the company’s stock valued at $21,092,000 after acquiring an additional 1,007,773 shares during the last quarter. 46.67% of the stock is owned by institutional investors and hedge funds.

Poseida Therapeutics Company Profile

(Get Rating)

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).

Recommended Stories

Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.